Core Insights - Abivax will present three scientific abstracts on obefazimod at the UEG Week 2024, focusing on its efficacy and safety in treating moderately to severely active ulcerative colitis [1][2] - The presentations will include data from a Phase 2b trial, highlighting the drug's potential to change treatment paradigms for ulcerative colitis patients [2] Company Overview - Abivax is a clinical-stage biotechnology company based in France and the United States, specializing in therapeutics for chronic inflammatory diseases [4] - The lead drug candidate, obefazimod, is currently in Phase 3 clinical trials for ulcerative colitis and has shown positive results in earlier trials [3][4] Drug Development - Obefazimod is an orally administered small molecule that may enhance the expression of microRNA miR-124, with a pivotal global Phase 3 trial program (ABTECT Program) initiated in October 2022 [3] - A Phase 2b clinical trial for Crohn's disease is expected to start in Q3 2024, and the company is exploring combination therapy opportunities for ulcerative colitis [3]
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024